Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
      Body Height* ; Growth*; Adalimumab/*therapeutic use ; Crohn Disease/*pathology ; Infliximab/*therapeutic use ; Tumor Necrosis Factor-alpha/*antagonists & inhibitors; Adolescent ; Child ; Crohn Disease/drug therapy ; Female ; Follow-Up Studies ; Humans ; Male ; Retrospective Studies ; Tumor Necrosis Factor-alpha/immunology
    • Abstract:
      Competing Interests: The authors have declared that no competing interests exist.
      Inflammation contributes to growth failure associated with inflammatory bowel diseases. Anti-TNFα therapy induces sustained remission and short-term improvements in height velocity and/or height standard deviation score (H-SDS) patients with Crohn's disease. The purpose of this study was to evaluate growth and adult height in patients with Crohn's disease taking maintenance infliximab or adalimumab therapy.This university-hospital based retrospective study included 61 patients, with a median follow-up of 2.6 years (2.0; 3.3). 38 patients (62%) reached their adult height. H-SDS was collected at diagnosis and together with disease activity markers (Harvey-Bradshaw Index, albumin, and C-reactive protein) at treatment initiation (baseline), and follow-up completion. Wilcoxon's signed-rank test was chosen for comparisons. Median H-SDS decreased from diagnosis to baseline (-0.08 [-0.73; +0.77] to -0.94 [-1.44; +0.11], p<0.0001) and then increased to follow-up completion (-0.63 [-1.08; 0.49], p = 0.003 versus baseline), concomitantly with an improvement in disease activity. Median adult H-SDS was within the normal range (-0.72 [-1.25; +0.42]) but did not differ from baseline H-SDS and was significantly lower than the target H-SDS (-0.09 [-0.67; +0.42], p = 0.01). Only 2 (6%) males had adult heights significantly below their target heights (10.5 and -13.5 cm [-1.75 and -2.25 SD]). In conclusion, anti-tumor necrosis factor α (TNF) therapy prevented loss of height without fully restoring the genetic growth potential in this group of patients with CD. Earlier treatment initiation might improve growth outcomes in these patients.
    • References:
      Metabolism. 2002 Jan;51(1):127-35. (PMID: 11782884)
      Clin Endocrinol (Oxf). 2010 Aug;73(2):220-8. (PMID: 20184596)
      Arch Dis Child. 1987 Feb;62(2):123-7. (PMID: 3548602)
      Horm Res Paediatr. 2011;75(1):8-13. (PMID: 20664179)
      Int J Mol Med. 2006 Dec;18(6):1011-8. (PMID: 17089003)
      Gut. 2006 Mar;55 Suppl 1:i16-35. (PMID: 16481629)
      J Crohns Colitis. 2012 Apr;6(3):337-44. (PMID: 22405171)
      Curr Med Res Opin. 2011 Mar;27(3):651-62. (PMID: 21241207)
      Gut. 2000 May;46(5):694-700. (PMID: 10764714)
      Eur J Clin Nutr. 1991 Jan;45(1):13-21. (PMID: 1855495)
      J Bone Miner Res. 2004 Nov;19(11):1805-12. (PMID: 15476580)
      Gastroenterology. 2012 Aug;143(2):365-74.e2. (PMID: 22562021)
      Dig Liver Dis. 2004 May;36(5):342-7. (PMID: 15191204)
      Inflamm Bowel Dis. 2005 May;11(5):435-41. (PMID: 15867582)
      Eur J Pediatr. 1990 Jul;149(10):687-90. (PMID: 2209659)
      J Crohns Colitis. 2013 Jun;7(5):369-76. (PMID: 22483567)
      Pediatrics. 2006 Jul;118(1):124-9. (PMID: 16818557)
      Inflamm Bowel Dis. 2014 Jul;20(7):1177-86. (PMID: 24865777)
      Gastroenterology. 2014 Feb;146(2):383-91. (PMID: 24162032)
      Inflamm Bowel Dis. 2011 Jun;17(6):1314-21. (PMID: 21560194)
      Pediatr Res. 1998 Oct;44(4):563-71. (PMID: 9773847)
      J Crohns Colitis. 2014 Oct;8(10):1179-207. (PMID: 24909831)
      Inflamm Bowel Dis. 2007 Apr;13(4):424-30. (PMID: 17206672)
      Gut. 2002 Jul;51(1):26-9. (PMID: 12077087)
      Aliment Pharmacol Ther. 2003 Apr 1;17(7):913-21. (PMID: 12656694)
      Scand J Gastroenterol. 2011 Apr;46(4):420-7. (PMID: 21114432)
      J Gastroenterol. 2012 Jun;47(6):647-54. (PMID: 22322660)
      J Pediatr Gastroenterol Nutr. 1993 May;16(4):373-80. (PMID: 8315544)
      Aliment Pharmacol Ther. 2005 May 1;21(9):1063-71. (PMID: 15854167)
      J Gastroenterol. 2010 Mar;45(3):277-84. (PMID: 20072791)
      Inflamm Bowel Dis. 2011 Oct;17(10):2144-52. (PMID: 21287665)
      Lancet. 1980 Mar 8;1(8167):514. (PMID: 6102236)
      Gastroenterology. 2010 Aug;139(2):430-8. (PMID: 20417635)
    • Accession Number:
      0 (Tumor Necrosis Factor-alpha)
      B72HH48FLU (Infliximab)
      FYS6T7F842 (Adalimumab)
    • Publication Date:
      Date Created: 20160917 Date Completed: 20170814 Latest Revision: 20190212
    • Publication Date:
      20250114
    • Accession Number:
      PMC5026336
    • Accession Number:
      10.1371/journal.pone.0163126
    • Accession Number:
      27636201